



What's Happening at GRS



News letter #3; July 5th, 2012

Visit: <http://www.ghresearchsociety.org>

Endo 2012, 94th Annual Meeting, Houston, Texas

- June 23 - 28, 2012
- ~7,000 Attendees
- Terribly 'hot' weather in Houston. Each day was near or over 100°F.....Ouch!!
- Many Symposium and Oral Sessions were concerning Obesity and Type 2 Diabetes
- There were no GH related Plenary talks and only a few in Symposia or Oral Sessions (see below)
- Please contact members of the Endo 2013 Annual Meeting Steering Committee (AMSC) before their August 10-12, 2012 meeting and let them know we would like at least one GH Symposium and/or Oral Session in upcoming Endo Meetings. The 2013 AMSC Chair is D. Robins, PhD who can be reached at: drobins@umich.edu

Selected ENDO 2012 Symposium/Oral Presentations

- *Targeting the Prolactin Receptor in Ovarian Cancer*, Ameae Walker
- *Targeting Prolactin Signaling in Prostate Cancer*, Marja Nevaiainen
- *Prolactin and Breast Cancer: Insights from Mouse Models*, Linda Schuler
- *Animal Models of the GH.IGF Axis: What Do They Tell Us about Aging*, Darlene Berryman
- *Novel Actions of GH on Macrophage Polarization Results in Paradoxical Effects of GH on Glucose Homeostasis*, Chunxia Lu
- *Changes in IGF-I Bioactivity Do Not Parallel Changes in Total IGF-I during GH Treatment of GH Deficient Adults*, Almee Varewijck

Upcoming Events

- GRS-IGF Meeting
 - Munich (Oct 17-20, 2012)
 - **See advertisement below!!**
- GRS-IGF Meeting
 - Singapore (Oct 14-19, 2014)
- GRS-IGF Meeting
 - Manchester (2016, date TBD)
- Other Upcoming Workshop
 - Safety of rhGH treatment (2013; date TBD)

SAVE THE DATE!

The 9th International Congress of the GRS and IGF Society

October 17 - 20, 2012
Munich - Germany

www.grs-igf2012.org

Late breaking abstracts can be submitted between
July 9-18, 2012

See GRS web site for details or go to

<http://www.grs-igf2012.org>



What's Happening at GRS



Page 2

Visit: <http://www.ghresearchsociety.org>

Supporting Member News

Report from the GRS Council Supporting Member Breakfast, Houston, Texas; Saturday, June 23, 2012

- A productive breakfast meeting was held with several members of GRS Council and our Supporting Members. Issues reviewed included the status of the Prader-Willi Consensus Statement (which will be submitted for publication shortly) and the upcoming 'Safety of hGH Treatment' workshop.
- As with previous breakfast meetings, this one was a casual and valuable get together with significant issues discussed. GRS intends to continue these types of meetings.

Satellite Sessions at our Meetings (as announced in the last newsletter). We encourage our Supporting Members to organize a Satellite Session at our upcoming meeting in Munich

- The timing of satellite meetings must not conflict with GRS meeting times
 - They may occur before or after the GRS-IGF meeting sessions or may be held as a breakfast meeting
- Host of the Satellite meeting will organize and support the entire event
- Speakers for the Satellite meeting must be submitted to GRS-IGF Program Organizing Committee for approval (so as not to conflict with speakers in the GHR-IGF Meeting)

GRS thanks our Supporting Members for your continued and enthusiastic support!

In these next several GRS Newsletters, will we highlight our Honorary Members



Raymond Hintz

Several years ago, GRS honored one of its founders and former president, Professor Emeritus Raymond Hintz, with an honorary membership. Ray has been instrumental in unraveling the GH-IGF axis and has been a leader in the field for 4 decades. He trained in the University of North Carolina during the initial days of the formation of our understanding of the biology of GH and has been the co-discoverer of the IGF-binding proteins. Soon afterwards, he settled in Stanford University where he created a leading research and training program in the field. His career spanned the spectrum of basic research, clinical research, teaching and patient care. He trained dozens of fellows, received scores of grants, was bestowed many honors and awards, and authored hundreds of papers. His lab developed important novel assays for GH-IGF axis components including, for example, the first ALS assay. Arguably, Ray's greatest contribution to the field has been his leadership in advancing GH therapy to new indications beyond GHD, most notably, ISS, with his classic paper in NEJM, paving the way to the approval of GH for this condition. Dr. Hintz retired from Stanford University in 2006 and lives in Palo Alto with his wife Carol. He continues to attend academic meetings. His work continues to influence and inspire all of us in the field.